Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cancer vaccine heat shock protein peptide complex-96 - Agenus; Cancer vaccine HSPPC-96; G-100; G-200; Heat shock protein peptide complex 96 cancer vaccine - Agenus; Heat-shock protein-based vaccine; HSPPC-96; NP-150; Oncophage; Prophage series G-100 vaccine; Prophage series G-200 vaccine; Prophage™ heat shock protein-based autologous vaccine

Latest Information Update: 19 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fordham University; Mount Sinai School of Medicine
  • Developer Agenus; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Cancer vaccines; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Malignant melanoma; Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Glioma; Malignant melanoma
  • No development reported Brain cancer; Colorectal cancer; Gastric cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Discontinued Chronic myeloid leukaemia; Leukaemia; Sarcoma

Most Recent Events

  • 01 May 2023 The Alliance for Clinical Trials in Oncology terminates a phase II trial for Glioma/GBM (Combination therapy) in USA (Intradermal, Infusion) (NCT01814813)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer(In children, In infants) in USA (Intradermal)
  • 17 Jan 2017 Agenus and National Cancer Institute plan a phase II trial of vitespen and pembrolizumab for Glioma (Combination therapy, Newly diagnosed) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top